Brad Bolon

Cutting Edge Congress
,

Dr. Bolon’s training includes earned DVM and MS degrees from the University of Missouri, a veterinary anatomic pathology residency at the University of Florida, and a PhD from Duke University while completing postdoctoral training at the Chemical Industry Institute of Toxicology. Professional experiences include contract research (Pathology Associates International, 1993-1996); basic research in pharmaceutical (Wyeth-Ayerst Research, 1996-1997) and biopharmaceutical (Amgen, 1997-2004) firms; and academia (The Ohio State University College of Veterinary Medicine, 2011-2015); responsible for evaluating engineered rodents and the efficacy of novel biopharmaceuticals. His principal role has been experimental pathology consulting as founder of GEMpath (2004 to date). Brad is a Diplomate of the American College of Veterinary Pathologists (DACVP, anatomic pathology; 1991) and American Board of Toxicology (DABT; 1996, re-certified 2001, 2006, 2011, 2016, 2021) and is a Fellow of the Academy of Toxicological Sciences (FATS; 2011, re-accredited 2016, 2021), International Academy of Toxicologic Pathology (FIATP; 2007), and Royal College of Pathologists (FRCPath, 2019).  He has written or co-authored nearly 300 papers and book chapters, has edited or co-edited 5 pathology books, and is a regular speaker at national and international meetings on toxicologic neuropathology related to the discovery and development of biomolecules, cell and gene therapies, medical devices, and small molecules. His lair is currently located in Longmont, Colorado, USA